

# Lab-based feasibility and acceptability of neuromuscular electrical stimulation in hip osteoarthritis rehabilitation

Journal of Rehabilitation and Assistive Technologies Engineering  
Volume 8: 1–10  
© The Author(s) 2021  
DOI: 10.1177/2055668320980613  
journals.sagepub.com/home/jrt



Louise C Burgess<sup>1</sup> , Paul Taylor<sup>2,3,4</sup>, Thomas W Wainwright<sup>1,5</sup>  
and Ian D Swain<sup>1</sup> 

## Abstract

**Introduction:** Neuromuscular electrical stimulation (NMES) could provide an alternative or adjunct treatment modality to induce muscle hypertrophy in the hip osteoarthritis population. This preliminary study evaluates the feasibility and acceptability of NMES to evoke involuntary muscle contractions in adults with advanced hip osteoarthritis.

**Methods:** Thirteen adults with moderate-to-severe hip osteoarthritis and fifteen healthy, older adults were invited to a lab-based testing session. NMES was applied unilaterally to the knee extensors and hip abductors for one continuous, five-minute testing session. Data were collected on device acceptability, tolerability and muscle contractile force, and compared between groups.

**Results:** Electrical stimulation of the knee extensors elicited a visible muscular contraction in 11 participants (85%) with hip osteoarthritis and 15 controls (100%) at an intensity acceptable to the participant. Electrical stimulation of the hip abductors elicited a muscular contraction in eight participants (62%) with osteoarthritis, and ten controls (67%). Muscle contractile force, pain, discomfort and acceptability did not differ between groups, however NMES of the knee extensors was favoured across all measures of assessment when compared to the hip abductors.

**Conclusions:** Electrical stimulation of the knee extensors may be a feasible and acceptable treatment modality to address muscle atrophy in adults with advanced hip osteoarthritis.

## Keywords

Rehabilitation devices, rehabilitation, electrical stimulation, hip osteoarthritis, NMES

Date received: 27 June 2020; accepted: 24 November 2020

## Background

Bilateral lower-limb muscle weakness and fatigue are features of individuals with advanced hip osteoarthritis,<sup>1–6</sup> which can lead to functional disability and an increased risk of further morbidity and mortality.<sup>7,8</sup> To counteract musculoskeletal impairment, local muscle strengthening and aerobic exercise are recommended irrespective of age, comorbidity, pain severity or disability.<sup>9–12</sup> Likewise, when progression of the disease leads to consideration for total hip replacement surgery, preoperative exercise programmes are proposed as a potential method to expedite recovery time.<sup>13–15</sup> Nonetheless, some patients choose to avoid traditional exercise due to fear of causing joint damage or exacerbating pain,<sup>16–20</sup> and the evidence supporting physiotherapy prior to hip replacement for improving function is equivocal.<sup>13</sup>

<sup>1</sup>Orthopaedic Research Institute, Bournemouth University, Bournemouth, UK

<sup>2</sup>Department Clinical Science and Engineering, Salisbury District Hospital, Salisbury, UK

<sup>3</sup>Odstock Medical Limited, Salisbury District Hospital, Salisbury, UK

<sup>4</sup>Faculty of Health and Social Science, Bournemouth University, Bournemouth, UK

<sup>5</sup>Physiotherapy Department, The Royal Bournemouth Hospital, Bournemouth, UK

### Corresponding author:

Louise C Burgess, Orthopaedic Research Institute, Bournemouth University, Executive Business Centre, 89 Holdenhurst Road, Bournemouth BH8 8EB, UK.

Email: lburgess@bournemouth.ac.uk



Neuromuscular electrical stimulation (NMES) is an alternative treatment that can counteract muscle weakness in adults with advanced progressive diseases; and has long been used to preserve or restore skeletal muscle mass and function during and after a period of disuse due to injury, surgery, or illness.<sup>21–23</sup> NMES involves the application of electrical impulses to skeletal muscles, by means of surface electrodes placed over the muscle belly, with the ultimate goal to evoke visible muscular contractions.<sup>22</sup> The activation pattern of these contractions differs substantially from that of voluntary contractions, whereby motor units are recruited in a non-selective, spatially fixed, and temporally synchronous pattern.<sup>24</sup> Whilst the force contracted through muscle stimulation is not greater than that of voluntary isometric contractions, it can be used where the pathology prevents voluntary exercise at either sufficient intensity or duration to be effective, with the end goal of moving onto voluntary exercise when strength and tolerance permits.<sup>25–27</sup> In addition, it can be used as an adjunct modality to enhance the strengthening effects of an existing rehabilitation programme, or support patients with muscle weakness who cannot tolerate high-intensity exercise or a high-volume of low-intensity exercise.<sup>21</sup>

Despite the evidence supporting electrical stimulation as a method to improve muscle strength, voluntary activation and functional recovery, NMES therapy remains clinically underutilised in orthopaedic practice.<sup>22,28,29</sup> Moreover, whilst there has been an expansion of research in the area of knee osteoarthritis and NMES for strength improvements, investigations within hip osteoarthritis are sparse.<sup>23,30</sup> NMES may offer a promising alternative approach to counteract muscle inhibition and minimise atrophy and thus restore normal muscle function more effectively than voluntary exercise alone. This preliminary study aims to investigate the feasibility and patient acceptability of using NMES as a treatment option to counteract muscle weakness amongst adults with advanced hip osteoarthritis. Data are compared to healthy adults, to observe any differences in response to NMES that may be attributable to hip joint pathology.

## Methods

### Participants

This is an observational case-control study recruiting two study groups: i) adults with a clinical diagnosis of unilateral or bilateral hip osteoarthritis and ii) healthy adults aged over 60 years (control group) between 12th November 2019 and 15th March 2020. Participants were recruited from the local area through online advertisement and email recruitment sent to local

organisations. Sixty years was chosen as the minimum age for the control group as osteoarthritis of the hip increases between the ages of 45 and 75,<sup>31</sup> and the average age for total hip replacement surgery is  $68.0 \pm 11.4$  years.<sup>32</sup> Participants were included in the hip osteoarthritis group if they had: i) received a clinical diagnosis of hip osteoarthritis from their general practitioner, an orthopaedic specialist or a physiotherapist; ii) presented with chronic joint pain for at least three months; iii) had an Oxford Hip score<sup>33</sup> of less than 40; and iv) were not on the waiting list for total hip replacement surgery. Participants were included in the control group if they were over 60 years old with no significant musculoskeletal comorbidities or neurological diseases. Exclusion criterion for both groups included: i) neurological disease affecting walking ability; ii) rheumatoid arthritis; iii) fitted with a pacemaker or other active medical implant; iv) uncontrolled epilepsy; v) sepsis or osteomyelitis; vi) known metastatic tumour involving the hip; vii) poor skin condition that prevented the use of self-adhesive electrodes; viii) not physically able to complete the testing protocol or ix) not able to provide informed consent. The experimental protocol was approved by the institutional ethics committee on 5th September 2019. In keeping with good practice, the ethical principles for medical research outlined in the Declaration of Helsinki were followed.<sup>34</sup> The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement for the reporting of cross-sectional studies was used to guide the reporting of this study.<sup>35</sup>

### Electrical muscle stimulation device

The NMES device chosen for this study was the Orthopaedic Microstim 2V2 neuromuscular stimulator (developed by Odstock Medical Ltd, Salisbury, UK). The device has been developed for general orthopaedic use, and for following joint replacement surgery, and consists of a stimulator box with two leads which are connected to two multiple use self-adhesive electrodes. It includes specific programmes to target muscle conditioning, endurance or power, in addition to programmes aimed at improving venous return and preventing thrombosis and pain relief modes. The programme chosen for this study was mode 0 (“set-up”) which is most appropriate when first evaluating electrode positioning and stimulation intensity. Whilst it is more common for an intermittent stimulation to be delivered within clinical practice, this mode delivers a continuous stimulation output, which is useful for determining individual responses to NMES with a controlled approach. The mode delivers a frequency of 40 Hz and a pulse duration of 300 $\mu$ s.

### Procedures


Participants were invited to attend a laboratory-based testing session. Participants were shown the NMES device and given instructions on how to operate it. The device was fitted by a researcher to the knee extensors and hip abductors of the participants. These muscle groups were chosen due to their importance for activities of daily living,<sup>36–38</sup> and susceptibility to weakness and atrophy in hip osteoarthritis.<sup>1,2,39</sup> NMES was applied unilaterally, to the affected limb of the participants with hip osteoarthritis, and to the right limb of the control group. For participants with bilateral hip osteoarthritis, NMES was applied to the more severely affected limb. To stimulate the knee extensors (the quadriceps femoris muscle group), two PALS platinum 70 mm (2.75") round electrodes were positioned on the vastus lateralis and vastus medialis, in line with manufacturer instructions (Figure 1). For the hip abductors (gluteus medius, gluteus minimus and tensor faciae latae), two 70 mm round electrodes were placed over the proximal and distal components of the gluteus medius (Figure 2). Once the device was fitted,

the participant operated the device independently for a period of around five minutes. Data were collected on device acceptability, tolerability and muscle contractile force and compared between groups to observe any differences in response to NMES in participants with hip osteoarthritis and healthy, age-matched controls.


### Variables

Age, weight, height and medical history were recorded from all participants. Affected side(s), duration of symptoms and the use of analgesia for pain relief were recorded from the participants in the hip osteoarthritis group. The subjective severity of hip pain when weight bearing was rated using the Numeric Pain Rating (NPR) scale (range 0–10 with 0 depicting no pain and 10 representing unbearable pain) and the severity of symptoms were quantified using the Oxford Hip Score.<sup>33</sup>

**Tolerability.** Once the device was fitted, participants independently operated the device and were instructed to gradually increase the current intensity, starting at



**Figure 1.** Electrode positioning during electrical stimulation of the knee extensors.



**Figure 2.** Electrode positioning during electrical stimulation of the hip abductors.

10 mA, until a visible involuntary muscle contraction was produced. If it was not possible to produce an involuntary muscle contraction, the participant was asked to increase the current intensity to the maximum tolerated for a period of around five minutes. Each mark on the stimulator corresponded to approximately 10 mA. The current intensity required to elicit an involuntary muscle contraction, or maximum current intensity tolerated, was recorded as a measure of device tolerability.

**Pain and discomfort.** Pain and discomfort were also used as measures of device tolerability. Pain during muscle contraction was recorded using a Numeric Rating Scale (NRS), with a score of zero describing no pain at all, and a score of 10 depicting the worst pain imaginable. If no visible muscle contraction was elicited, pain was recorded during the maximum stimulation intensity tolerated by the participant. Discomfort was assessed through the administration of a Likert Scale questionnaire that has previously been used to quantify discomfort associated with NMES.<sup>40,41</sup> Participants were asked to score their discomfort in comparison to a blood pressure cuff inflated on the arm on a scale of one to five, with a score one depicting no discomfort and a score of five describing severe discomfort.

**Muscle contractile force.** To evaluate if the current intensity tolerated was sufficient to evoke an involuntary muscle contraction, and the relative feasibility of the device within rehabilitation, the strength of muscle contraction produced by NMES was scored through visual inspection and the definitions used in the Medical Research Council's scale (MRC scale) of muscle power.<sup>42</sup> Although it does not measure strength itself, the MRC scale is the most commonly accepted method of evaluating volitional muscle activation and has proven to be reliable and accurate for clinical assessment in weak muscles.<sup>43</sup>

Once an involuntary muscle contraction was produced, or the participant had reached the maximum intensity of stimulation tolerable, the muscle contraction was graded independently by one researcher using the descriptions in Table 1. For example, if the NMES device could not activate a muscle contraction (no trace or flicker), the investigator would award a score of zero. If a flicker or trace of muscle activation was observed, a score of one was awarded. During knee extensor stimulation, the participant was seated on the end of a plinth, other than during the assessment of MRC grade 2. For this assessment, the participant was side lying with their leg supported. For hip abduction, the participant was side lying, with their test side up.

**Table 1.** MRC scale of muscle power, used with permission of the Medical Research Council.

Score	Description
0	No muscle activation
1	Trace muscle activation, such as a twitch, without achieving full range of motion
2	Muscle activation without gravity resistance, achieving full range of motion
3	Muscle activation against gravity, full range of motion
4	Muscle activation against some resistance, full range of motion
5	Muscle activation against examiner's full resistance, full range of motion

**Acceptability.** At the end of the testing session, participants were asked if they would consider using the device in a treatment routine (yes/no answer), and to provide any other comments or opinions about the NMES device.


### Sample size and statistical methods

A formal sample size calculation was not considered appropriate given the study design.<sup>44</sup> Following recommendations for the design of usability studies in medical devices,<sup>45</sup> a sample size of 15 participants per group was sought. Data were compared between groups to observe any differences in response to NMES that may be a result of hip joint pathology.

All data were analysed using IBM SPSS Statistics version 26 (SPSS Inc., Chicago, USA), with the significance level set at  $p < 0.05$ . Normality of the numerical data were analysed using a Shapiro-Wilk test. If both samples passed the preliminary normality test, an independent samples  $t$  test was conducted.<sup>46</sup> The current intensity data were not normally distributed, and hence, a Mann-Whitney  $U$  test was conducted to compare tolerability between groups. Mean (standard deviation) and median (interquartile range (IQR)) were used to describe normally and non-normally distributed data, respectively.<sup>47</sup> Categorical data were analysed using a Fisher's exact test (two variables) or a Pearson's chi-squared (more than two variables) and results were presented as percentages. Participant feedback on acceptability was categorised into key themes and reported using a descriptive analysis.

## Results

Fifty-eight individuals volunteered to take part in the study (Figure 3). During the initial telephone consultation, 16 volunteers did not meet the inclusion criteria due to: musculoskeletal comorbidity ( $n = 6$ ); prior joint



**Figure 3.** Participant recruitment through the study.

replacement ( $n = 5$ ); hip pain but no clinical diagnosis of osteoarthritis ( $n = 2$ ); cardiovascular comorbidity ( $n = 1$ ), fitted with a pacemaker ( $n = 1$ ); and listed for total hip replacement surgery ( $n = 1$ ), and were excluded from the study. Six participants declined participation due to travel or time commitments. A total of 36 were invited to attend the testing session. Two participants in the control group were excluded during the eligibility assessment due to knee pathology not previously disclosed. A further six participants were unable to attend the testing session due to the COVID-19 pandemic and the Government advice to close higher education institutes. Hence, the study was prematurely closed on 15th March 2020. This analysis includes 28 participants who were recruited prior to the pandemic (hip osteoarthritis,  $n = 13$ ; control group,  $n = 15$ ).

There were no differences between groups in terms of age ( $p = 0.39$ ) or gender distribution ( $p = 1.00$ ). The hip osteoarthritis group had a significantly higher BMI than the control group ( $p = 0.03$ ). Participants with hip

osteoarthritis group had a mean Oxford Hip Score of  $28 \pm 7.81$  (range: 18–39), suggesting moderate-to-severe hip osteoarthritis.<sup>33</sup> The mean duration of symptoms was  $4.04 \pm 3.17$  years (range: 6 months–10 years) and mean VAS pain on weight bearing was  $5.31 \pm 1.49$  (range 3–8) (Table 2). Six participants were not taking any analgesics, four were taking paracetamol or ibuprofen when required, one was taking codeine and paracetamol, one was taking the maximum dose of paracetamol, and one participant was taking diahydrocodine in addition to cod liver oil.

### Tolerability

All participants were comfortable with the NMES sensation and tolerated electrical stimulation of the knee extensors and hip abductors for the testing period. The median current intensity tolerated during knee extensor stimulation in the osteoarthritis group was 45 mA (IQR: 40–50), and 47 mA (IQR 40–50) in the control group. The median current intensity tolerated during

**Table 2.** Characteristics of participants.

Characteristic	Unilateral hip OA n = 11	Bilateral hip OA n = 2	All hip OA n = 13	Control group n = 15
Age (years)	75 ± 7.69	72 ± 4.95	75 ± 7.30	72 ± 6.42
Males, n (%)	4 (36%)	1 (50%)	5 (38%)	5 (33%)
Height (m)	1.68 ± 0.08	1.70 ± 9.90	1.68 ± 0.08	1.68 ± 0.12
Weight (kg)	83.0 ± 18.29	91.00 ± 4.24	84.23 ± 17.01	71.85 ± 14.89
BMI (kg/m <sup>2</sup> )	29 ± 6	32 ± 2	30 ± 6	25 ± 4
Oxford Hip Score	27 ± 7	34 ± 5	28 ± 7	N/A
Pain (VAS)	5.79 ± 1.62	5.5 ± 0.71	5.31 ± 1.49	N/A
Duration of symptoms (years)	3.68 ± 2.82	6.0 ± 5.66	4.04 ± 3.17	N/A

**Table 3.** Discomfort experienced during electrical stimulation of the knee extensors and hip abductors in adults with hip osteoarthritis, compared to healthy older adults.

Discomfort	Knee extensors			Hip abductors		
	Osteoarthritis	Control	Sig (2-tailed)	Osteoarthritis	Control	Sig (2-tailed)
Minimal discomfort	13 (100%)	11 (73%)	$p = 0.13$	8 (62%)	11 (73%)	$p = 0.72$
Mild discomfort	0	3 (20%)		2 (15%)	1 (7%)	
Moderate discomfort	0	1 (7%)		3 (23%)	3 (20%)	

hip abductor stimulation in the osteoarthritis group was 45 mA (IQR: 40–50) and 40 mA (IQR: 40–50) in the control group. Self-selected maximum stimulation intensity did not differ between groups during electrical stimulation of the knee extensors ( $p = 0.89$ ) or hip abductors ( $p = 0.45$ ).

### Pain and discomfort

Pain during electrical stimulation was reported by one participant from each group during stimulation of the knee extensors. Pain was scored as 1/10 by the participant with osteoarthritis, and 4/10 by the participant in the control group. Pain during electrical stimulation of the hip abductors was reported by four participants (31%) in the osteoarthritis group (range: 2–7), and by three participants (20%) in the control group (range: 3–7). No discomfort was reported by the osteoarthritis group during stimulation of the knee extensors. Discomfort was more commonly reported during stimulation of the hip abductors (Table 3). There were no differences in discomfort between the osteoarthritis and control group during electrical stimulation of the knee extensors ( $p = 0.13$ ) or hip abductors ( $p = 0.72$ ).

### Muscle contractile force

Neuromuscular electrical stimulation of the knee extensors evoked an involuntary muscular contraction in 11 participants (85%) in the hip osteoarthritis group and

15 participants (100%) in the control group, at a stimulation intensity acceptable to the participant. Electrical stimulation of the hip abductors evoked an involuntary muscular contraction in eight participants (62%) in the osteoarthritis group, and ten participants (67%) in the control group. Muscle contractile force, as measured by the MRC scale for muscle power, was not significantly different between study groups during stimulation of the knee extensors ( $p = 0.29$ ) or hip abductors ( $p = 1.00$ ). However, muscle contractile force was greater in the knee extensors, when compared to the hip abductors, in both study groups (Table 4).

### Acceptability

All participants in both study groups reported that they would consider using electrical stimulation of the knee extensors and hip abductors in a treatment routine. Two participants in the osteoarthritis group and two in the control group expressed concern with the process of independently locating the muscles and placing electrodes. Two participants in the osteoarthritis group reported pain relief during stimulation of the hip abductors. Five participants in the control group said they would not have been able to tolerate a current higher than their self-selected maximum. One participant in the control group referred to the device as distracting rather than uncomfortable, and one described it as a useful alternative or adjunct to conventional exercise.

**Table 4.** Muscle contractile force during unilateral electrical stimulation of the knee extensors and hip abductors in adults with hip osteoarthritis, compared to healthy older adults.

MRC grade	Knee extensors			Hip abductors		
	Osteoarthritis	Control	Sig (2-tailed)	Osteoarthritis	Control	Sig (2-tailed)
0 No muscle activation	2 (15%)	0	$p = 0.29$	5 (39%)	5 (33%)	$p = 1.00$
1 Trace muscle activation	1 (8%)	4 (27%)		8 (62%)	10 (67%)	
2 Activation without gravity resistance	9 (69%)	10 (67%)		0	0	
3 Activation against gravity	1 (8%)	1 (7%)		0	0	

## Discussion

Electrical muscle stimulation has a long-established place in therapy practice<sup>48</sup> and has been shown to preserve or restore muscle mass and aspects of neuromuscular function in a range of musculoskeletal conditions, including both acute injuries and chronic conditions.<sup>23</sup> Nonetheless, NMES therapy remains clinically underutilised in the hip osteoarthritis population.<sup>30</sup> The slow transition of NMES into clinical practice has been attributed to a lack of guidelines on stimulation parameters, uncertainty regarding the feasibility of stimulation for inducing strength gains, and concerns of intolerance in patients particularly sensitive to electrical stimulation.<sup>22</sup> A key component of assessing the feasibility of clinical interventions is patient acceptability, which relates to how the intended recipients react to the intervention.<sup>49</sup> In this preliminary study, the feasibility and acceptability of the NMES device were measured in a cohort of participants with advanced hip osteoarthritis, and compared to a cohort of healthy, age-matched controls, to observe any differences in stimulation response attributable to hip joint pathology.

Neuromuscular electrical stimulation of the knee extensors elicited a visible muscular contraction in 11 participants (85%) in the hip osteoarthritis group and 15 participants (100%) in the control group, at a stimulation intensity acceptable to the participant. Electrical stimulation of the hip abductors elicited a muscular contraction in eight participants (62%) in the osteoarthritis group, and ten participants (67%) in the control group. Muscle contractile force, pain, discomfort and acceptability did not differ between groups, however electrical stimulation of the knee extensors was favoured across all measures of assessment when compared to the hip abductors in both groups. These findings suggest that electrical stimulation of the knee extensors may be an efficacious and acceptable treatment modality to address muscle weakness in the hip osteoarthritis population. These findings are perhaps not surprising, given the evidence for NMES alone or combined with exercise for quadriceps

strengthening in patients with osteoarthritis of the knee,<sup>50</sup> but nonetheless provide important information for future research endeavours in this area.

Importantly, no differences were observed in muscle contractile force between the two study groups during stimulation of the knee extensors or hip abductors. NMES involves the application of electrical impulses to skeletal muscles, by means of surface electrodes placed over the muscle belly, with the ultimate goal to evoke visible muscle contractions.<sup>22</sup> The basic theoretical premise of electrical muscle stimulation is that if the peripheral nerve can be stimulated, the resulting excitation impulse will be transmitted along the nerve to the motor endplates in the muscle, producing a muscle contraction, which will have an eventual effect on muscle hypertrophy and strength.<sup>51</sup> Aerobic exercise and local muscle strengthening are recommended as core components in the management of hip osteoarthritis,<sup>9–11</sup> however, voluntary exercise may be inhibited by pain during joint loading. During electrical stimulation of the knee extensors, it was possible to achieve muscle activation and full range of motion in the majority of participants, with only two reports of pain. Clinically, these findings are important for patients who cannot perform conventional, voluntary exercise at either sufficient intensity or duration to be effective.

Interestingly, it was not possible to achieve a muscle contraction at a tolerable level of stimulation of the hip abductors in over one third of each study group, and the most powerful contraction elicited, as graded by the MRC scale, was a trace muscle activation. These findings may be explained by a higher percentage of fatty infiltration in the gluteal muscles when compared to the quadriceps and the substantial decrease in contractile tissues of the gluteal muscles evident in patients with hip osteoarthritis.<sup>52–55</sup> Due to the high resistivity of subcutaneous fat tissue, higher stimulus currents are required to evoke muscle contractions where there is higher skeletal muscle fat infiltration, which can lead to patient discomfort.<sup>56</sup> These predictions are supported by the assessment of tolerability, whereby both pain and discomfort were more frequently

reported in both study groups during electrical stimulation of the hip abductors when compared to the knee extensors. From these findings, we can anticipate that electrical stimulation of the knee extensors will be more acceptable than electrical stimulation of the hip abductors in the hip osteoarthritis population. These findings are promising given the success of NMES applied to the knee extensors in individuals with knee osteoarthritis, whereby electrical stimulation has been shown to increase strength, train endurance, minimise atrophy, reduce pain and increase range of motion.<sup>23,57</sup> Future research is required to examine the effectiveness of NMES for improving knee extensor strength and endurance in the hip osteoarthritis population.

## Limitations

A clear limitation of this study is the failure to meet the sample size sought due to a global pandemic and the premature completion of data collection. Participants were encouraged to answer the questions on the NMES device honestly and accurately. Nonetheless, we recognise an element of response bias may exist in the feedback of the device, whereby the participants felt they should report a favourable opinion.<sup>58</sup> It should be acknowledged that the size of the electrode used with electrical stimulation can markedly affect the stimulation response, and that choosing a larger electrode may have improved the strength of contraction. In addition, tolerance to stimulation can increase with repeated use,<sup>59</sup> and thus a higher current intensity may be achieved over time. The continuous contraction length used in this study may be less comfortable than the intermittent stimulation used most with NMES. Finally, the MRC grade is a subjective measure, and only quantifies the category of contraction strength, not strength itself.<sup>43</sup>

## Conclusions

Neuromuscular electrical stimulation of the knee extensors may be a feasible treatment method to address muscle weakness in the hip osteoarthritis population. NMES was well-tolerated and acceptable to participants and may serve as an alternative or adjunct treatment to improve muscle function for those who have difficulty participating in voluntary exercise. Future research evaluating the effectiveness of NMES for improving strength, endurance or minimising atrophy is required to progress these findings.

## Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PT is a Clinical Director of Odstock

Medical Limited, the company that supplied the device used in this study. PT and IS hold stocks in Odstock Medical Limited. LB and TW have no conflicting interests to declare.

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## Guarantor

LB.

## Contributorship

LB, IS, PT and TW conceived the study. LB, IS and PT were involved in protocol development, gaining ethical approval. LB recruited participants and analysed data. LB wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

## Acknowledgements

Not applicable.

## ORCID iDs

Louise C Burgess  <https://orcid.org/0000-0003-1870-9061>  
Ian D Swain  <https://orcid.org/0000-0002-3646-4603>

## References

1. Loureiro A, Constantinou M, Diamond LE, et al. Individuals with mild-to-moderate hip osteoarthritis have lower limb muscle strength and volume deficits. *BMC Musculoskelet Disord* 2018; 19: 303.
2. Loureiro A, Mills PM and Barrett RS. Muscle weakness in hip osteoarthritis: a systematic review. *Arthritis Care Res (Hoboken)* 2013; 65: 340–352.
3. Judd DL, Thomas AC, Dayton MR, et al. Strength and functional deficits in individuals with hip osteoarthritis compared to healthy, older adults. *Disabil Rehabil* 2014; 36: 307–312.
4. Constantinou M, Barrett R, Brown M, et al. Spatial-temporal gait characteristics in individuals with hip osteoarthritis: a systematic literature review and meta-analysis. *J Orthop Sports Phys Ther* 2014; 44: 291–B297.
5. Trouvin A-P and Perrot S. Pain in osteoarthritis. Implications for optimal management. *Joint Bone Spine* 2018; 85: 429–434.
6. Burgess LC, Taylor P, Wainwright TW, et al. Strength and endurance deficits in adults with moderate-to-severe hip osteoarthritis, compared to healthy, older adults. *Disabil Rehabil* 2020.
7. Turkiewicz A, Kiadaliri AA and Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. *Osteoarthritis Cartilage* 2019; 27: 848–854.
8. Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. *BMJ* 2011; 342: d1165.

9. National Institute of Health and Care Excellence. Clinical guideline [CG177] osteoarthritis: care and management. <https://www.nice.org.uk/guidance/cg177/chapter/1-Recommendations> (2014., accessed 13th March 2020).
10. American Academy of Orthopaedic Surgeons. *Management of osteoarthritis of the hip. Evidence-based clinical practice guidelines*. USA: American Academy of Orthopaedic Surgeons, 2017.
11. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* 2008; 16: 137–162.
12. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage* 2019; 27: 1578–1589.
13. Wang L, Lee M, Zhang Z, et al. Does preoperative rehabilitation for patients planning to undergo joint replacement surgery improve outcomes? A systematic review and Meta-analysis of randomised controlled trials. *BMJ Open* 2016; 6: e009857.
14. Ackerman IN and Bennell KL. Does pre-operative physiotherapy improve outcomes from lower limb joint replacement surgery? A systematic review. *Aust J Physiother* 2004; 50: 25–30.
15. Moyer R, Ikert K, Long K, et al. The value of preoperative exercise and education for patients undergoing total hip and knee arthroplasty: a systematic review and meta-analysis. *JBJS Rev* 2017; 5: e2.
16. Dobson F, Bennell KL, French SD, et al. Barriers and facilitators to exercise participation in people with hip and/or knee osteoarthritis: synthesis of the literature using behavior change theory. *Am J Phys Med Rehabil* 2016; 95: 372–389.
17. Kanavaki AM, Rushton A, Efstathiou N, et al. Barriers and facilitators of physical activity in knee and hip osteoarthritis: a systematic review of qualitative evidence. *BMJ Open* 2017; 7: e017042.
18. Petursdottir U, Arnadottir SA and Halldorsdottir S. Facilitators and barriers to exercising among people with osteoarthritis: a phenomenological study. *Phys Ther* 2010; 90: 1014–1025.
19. Hurley M, Dickson K, Hallett R, et al. Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review. *Cochrane Database Syst Rev* 2018; 4: CD010842–04.
20. Hunter DJ and Eckstein F. Exercise and osteoarthritis. *J Anat* 2009; 214: 197–207.
21. Jones S, Man WD, Gao W, et al. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane Database Syst Rev* 2016; 10: CD009419.
22. Spector P, Laufer Y, Elboim Gabyzon M, et al. Neuromuscular electrical stimulation therapy to restore quadriceps muscle function in patients after orthopaedic surgery: a novel structured approach. *J Bone Joint Surg Am* 2016; 98: 2017–2024.
23. Nussbaum EL, Houghton P, Anthony J, et al. Neuromuscular electrical stimulation for treatment of muscle impairment: critical review and recommendations for clinical practice. *Physiother Can* 2017; 69: 1–76.
24. Gregory CM and Bickel CS. Recruitment patterns in human skeletal muscle during electrical stimulation. *Phys Ther* 2005; 85: 358–364.
25. Lake DA. Neuromuscular electrical stimulation. An overview and its application in the treatment of sports injuries. *Sports Med* 1992; 13: 320–336.
26. Kramer JF and Mendryk SW. Electrical stimulation as a strength improvement technique: a review. *J Orthop Sports Phys Ther* 1982; 4: 91–98.
27. Selkowitz DM. Improvement in isometric strength of the quadriceps femoris muscle after training with electrical stimulation. *Phys Ther* 1985; 65: 186–196.
28. Bax L, Staes F and Verhagen A. Does neuromuscular electrical stimulation strengthen the quadriceps femoris? A systematic review of randomised controlled trials. *Sports Med* 2005; 35: 191–212.
29. Paillard T. Combined application of neuromuscular electrical stimulation and voluntary muscular contractions. *Sports Med* 2008; 38: 161–177.
30. Burgess LC, Swain ID, Taylor P, et al. Strengthening quadriceps muscles with neuromuscular electrical stimulation following total hip replacement: a review. *Curr Phys Med Rehabil Rep* 2019; 7: 275–283.
31. Versus Arthritis. *The state of musculoskeletal health 2019*. UK: Versus Arthritis, 2019.
32. National Joint Registry. 16th annual report, National Joint Registry, 2019.
33. Dawson J, Fitzpatrick R, Carr A, et al. Questionnaire on the perceptions of patients about total hip replacement. *J Bone Joint Surg Br* 1996; 78: 185–190.
34. World Medical Association. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects, [www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/](http://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) (2018, accessed 21 June 2019).
35. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg* 2014; 12: 1495–1499.
36. Grimaldi A, Richardson C, Stanton W, et al. The association between degenerative hip joint pathology and size of the gluteus medius, gluteus minimus and piriformis muscles. *Man Ther* 2009; 14: 605–610.
37. Elboim-Gabyzon M, Rozen N and Laufer Y. Quadriceps femoris muscle fatigue in patients with knee osteoarthritis. *Clin Interv Aging* 2013; 8: 1071–1077.
38. Foucher KC, Cinnamon CC, Ryan CA, et al. Hip abductor strength and fatigue are associated with activity levels more than 1 year after total hip replacement. *J Orthop Res* 2018; 36: 1519–1525.
39. Marshall AR, Noronha M, Zacharias A, et al. Structure and function of the abductors in patients with hip osteoarthritis: systematic review and meta-analysis. *J Back Musculoskelet Rehabil* 2016; 29: 191–204.

40. Wainwright TW, Burgess LC and Middleton RG. A feasibility randomised controlled trial to evaluate the effectiveness of a novel neuromuscular electro-stimulation device in preventing the formation of oedema following total hip replacement surgery. *Heliyon* 2018; 4: e00697.
41. Wainwright TW, Burgess LC and Middleton RG. A single-centre feasibility randomised controlled trial comparing the incidence of asymptomatic and symptomatic deep vein thrombosis between a neuromuscular electrostimulation device and thromboembolism deterrent stockings in post-operative patients recovering from elective total hip replacement surgery. *Surg Technol Int* 2020/04/07; 36: 289–298.
42. Medical Research Council. MRC muscle scale, <https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/> (2020, accessed 1 June 2020).
43. Naqvi U and Sherman A. *Muscle strength grading*. Treasure Island, FL: StatPearls, 2020.
44. Billingham SA, Whitehead AL and Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom clinical research network database. *BMC Med Res Methodol* 2013; 13: 104–108.
45. Wilkund M, Kendler J and Strohlic A. *Usability testing of medical devices*. 2nd ed. Florida: CRC Press, Taylor & Francis Group, 2016.
46. Rochon J, Gondan M and Kieser M. To test or not to test: preliminary assessment of normality when comparing two independent samples. *BMC Med Res Methodol* 2012; 12: 81.
47. Habibzadeh F. Statistical data editing in scientific articles. *J Korean Med Sci* 2017; 32: 1072–1076.
48. Watson T. *Electrotherapy: evidence-based practice*. Edingburgh: Churchill Livingstone, 2008.
49. Bowen DJ, Kreuter M, Spring B, et al. How we design feasibility studies. *Am J Prev Med* 2009; 36: 452–457.
50. de Oliveira Melo M, Aragao FA and Vaz MA. Neuromuscular electrical stimulation for muscle strengthening in elderly with knee osteoarthritis – a systematic review. *Complement Ther Clin Pract* 2013; 19: 27–31.
51. Azman MF and Azman AW. The effect of electrical stimulation in improving muscle tone (clinical). *IOP Conference Series: Materials Science and Engineering* 2017; 260 1–13.
52. Zacharias A, Pizzari T, English DJ, et al. Hip abductor muscle volume in hip osteoarthritis and matched controls. *Osteoarthritis Cartilage* 2016; 24: 1727–1735.
53. Rasch A, Bystrom AH, Dalen N, et al. Reduced muscle radiological density, cross-sectional area, and strength of major hip and knee muscles in 22 patients with hip osteoarthritis. *Acta Orthop* 2007; 78: 505–510.
54. Fukumoto Y, Ikezoe T, Tateuchi H, et al. Muscle mass and composition of the hip, thigh and abdominal muscles in women with and without hip osteoarthritis. *Ultrasound Med Biol* 2012; 38: 1540–1545.
55. Marcus RL, Addison O, Kidde JP, et al. Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. *J Nutr Health Aging* 2010; 14: 362–366.
56. Doheny EP, Caulfield BM, Minogue CM, et al. Effect of subcutaneous fat thickness and surface electrode configuration during neuromuscular electrical stimulation. *Med Eng Phys* 2010; 32: 468–474.
57. Novak S, Guerron G, Zou Z, et al. New guidelines for electrical stimulation parameters in adult patients with knee osteoarthritis based on a systematic review of the current literature. *Am J Phys Med Rehabil* 2020; 99: 682–688.
58. Smith PB. Response bias(es). In: Michalos AC (ed.) *Encyclopedia of quality of life and well-being research*. Dordrecht: Springer Netherlands, 2014, pp.5539–5540.
59. Alon G and Vs G. Tolerance and conditioning to neuromuscular electrical stimulation within and between sessions and gender. *J Sports Sci Med* 2005; 4: 395–405.